In these studies, ADAM-9 prodomain was highly specific and the inhibition of ADAM-9, by its recombinant prodomain, regulated ADAM-10 activity controlling the release of soluble α-secretase enzyme, which is an important task in the therapy Alzheimer's disease [99]. Here, ADAM9 is linked to Alzheimer disease.